The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure
NCT02284230 on ClinicalTrials.gov · last registry update 2015-08-24
Withdrawn before anyone was enrolled. The sponsor logged completion for August 2015. Primary outcome, as filed: Plasma glucose during oral glucose tolerance test at week 26. liraglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- WITHDRAWN
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Bo Feldt-Rasmussen
- Sponsor type
- Other
- Enrollment
- 0
- Started
- 2014-12
- Primary completion
- 2015-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Plasma glucose during oral glucose tolerance test at week 26
Conditions studied
Kidney Failure, Chronic · Prediabetic State
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.